Protocol Ledger

NCT05271409 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Interventional Phase III clinical trial protocol NCT05271409 sponsored by Roche / Genentech in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-30 Enrollment: 139 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05271409
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)139 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05271409
Protocol FieldVerified Registry Value
NCT IdentifierNCT05271409
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment139 participants (ACTUAL)
Registered Start Date2022-08-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI